Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307047 · ClinicalTrials.gov registry record · Phase 3
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
A Phase 3 study of Coronary Artery Disease, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,687
- Enrollment target
- 20
- Study locations
NCT00307047 is a Phase 3 study of Coronary Artery Disease that has completed, run by Abbott Medical Devices. The registered enrollment target is 3,687 participants, above the 1,270-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (190% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00307047, a Phase 3 study of Coronary Artery Disease, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,687 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®). The XIENCE V® arm will be compared to an active control, represented by the FDA-approved TAXUS® EXPRESS2™ Paclitaxel-Eluting Coronary Stent System (TAXUS®), commercially available from Boston Scientific. TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is manufactured by Boston Scientific.
Conditions Studied
Interventions
- DEVICE XIENCE V® Everolimus Eluting Coronary Stent
- DEVICE TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Study Locations (20)
California
- Inova Fairfax Hospital - Fairfax
- San Diego Cardiovascular Associates - La Jolla
- Scripps Memorial Hospital - La Jolla
- Good Samaritan Hospital - LA - Los Angeles
- Mercy General Hospital - Sacramento
- Sutter Medical Center of Santa Rosa - Santa Rosa
Colorado
- The Medical Center of Aurora - Aurora
- Poudre Valley Hospital - Fort Collins
Florida
- Sacred Heart Hospital - Pensacola
- Sarasota Memorial Hospital - Sarasota
Indiana
- St. Francis Hospital and Health Centers - Indianapolis
- The Heart Center of Indiana - Indianapolis
Kentucky
- Central Baptist Hospital - Lexington
- Jewish Hospital - Louisville
Arizona
- Scottsdale Healthcare - Scottsdale
Arkansas
- Arkansas Heart Hospital - Little Rock
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,687 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00307047
The ClinicalTrials.gov registry entry for NCT00307047 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,687 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,270-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (190% higher). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which XIENCE V® Everolimus Eluting Coronary Stent is the first listed.
NCT00307047 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00307047 about?
NCT00307047 is a clinical study titled "SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System". The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®). The XIENCE V® arm will be compared to an active control, represented by the FDA-approved TAXUS® EXPRESS2™ Paclitaxel-Eluting Coronary ...
What is the current status of trial NCT00307047?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,687 participants. The study started on 2006-08. Estimated completion is 2012-05.
What conditions does trial NCT00307047 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT00307047?
The interventions under investigation include: XIENCE V® Everolimus Eluting Coronary Stent (DEVICE), TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00307047?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00307047 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
RECRUITING · Phase 3
-
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.